12 studies found for:    "dyskeratosis congenita" OR "Dyskeratosis Congenita"
Show Display Options
Rank Status Study
1 Recruiting Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita
Conditions: Dyskeratosis Congenita;   Hoyeraal Hreidarsson Syndrome;   Revesz Syndrome;   Aplastic Anemia
Interventions: Biological: alemtuzumab;   Drug: Fludarabine;   Drug: Cyclosporins;   Drug: Mycophenolate mofetil
2 Active, not recruiting SCT for Dyskeratosis Congenita or SAA
Conditions: Dyskeratosis Congenita;   Aplastic Anemia
Interventions: Drug: Campath 1H;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Total Body Irradiation;   Procedure: Stem Cell Transplantation;   Drug: antithymocyte globulin;   Drug: Methylprednisolone
3 Not yet recruiting Hematopoietic Stem Cell Transplant for Dyskeratosis Congenita or Severe Aplastic Anemia
Conditions: Dyskeratosis Congenita;   Aplastic Anemia
Interventions: Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Biological: Stem Cell Transplant;   Drug: Anti-thymocyte globulin
4 Terminated Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita
Conditions: Fanconi Anemia;   Dyskeratosis Congenita
Intervention: Drug: danazol
5 Suspended
Has Results
Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation
Conditions: Thalassemia;   Sickle Cell Disease;   Glanzmann Thrombasthenia;   Wiskott-Aldrich Syndrome;   Chronic-granulomatous Disease;   Severe Congenital Neutropenia;   Leukocyte Adhesion Deficiency;   Schwachman-Diamond Syndrome;   Diamond-Blackfan Anemia;   Fanconi Anemia;   Dyskeratosis-congenita;   Chediak-Higashi Syndrome;   Severe Aplastic Anemia
Intervention: Drug: Alefacept
6 Completed Assessing Immune Function in Young Patients With Cytopenia That Did Not Respond to Treatment
Conditions: Dyskeratosis Congenita;   Fanconi Anemia;   Myelodysplastic Syndromes;   Pearson Marrow-pancreas Syndrome;   Shwachman-diamond Syndrome
Interventions: Genetic: polymerase chain reaction;   Other: flow cytometry;   Other: immunologic technique;   Procedure: biopsy
7 Completed Phase II Pilot Study of Granulocyte Colony-Stimulating Factor for Inherited Bone Marrow Failure Syndromes
Conditions: Shwachman Syndrome;   Fanconi's Anemia;   Dyskeratosis Congenita;   Thrombocytopenia
Intervention: Drug: filgrastim
8 Recruiting Abatacept Reduced Intensity for Non-Malignant Diseases
Conditions: Hurler Syndrome;   Fanconi Anemia;   Glanzmann Thrombasthenia;   Wiskott-Aldrich Syndrome;   Chronic Granulomatous Disease;   Severe Congenital Neutropenia;   Leukocyte Adhesion Deficiency;   Shwachman Diamond Syndrome;   Diamond Blackfan Anemia;   Dyskeratosis Congenita;   Chediak Higashi Syndrome;   Severe Aplastic Anemia;   Thalassemia;   Hemophagocytic Lymphohistiocytosis
Interventions: Drug: 4 doses of abatacept;   Drug: 6 doses of abatacept
9 Recruiting Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders
Condition: Non-Malignant Disease
Interventions: Drug: Treosulfan;   Drug: Fludarabine Phosphate;   Biological: Anti-Thymocyte Globulin;   Radiation: Total-Body Irradiation;   Procedure: Allogeneic Bone Marrow Transplantation;   Procedure: Peripheral Blood Stem Cell Transplantation;   Procedure: Umbilical Cord Blood Transplantation;   Drug: Tacrolimus;   Drug: Methotrexate;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Other: Laboratory Biomarker Analysis
10 Recruiting Cancer in Inherited Bone Marrow Failure Syndromes
Conditions: Aplastic Anemia;   Head and Neck Neoplasms;   Bone Marrow Failure
Intervention:
11 Recruiting Safety Study of Gene Modified Donor T Cell Infusion After Stem Cell Transplant for Non-Malignant Diseases
Conditions: Primary Immune Deficiency Disorders;   Hemophagocytic Lymphohistiocytosis;   Inherited Bone Marrow Failure Syndrome;   Hemoglobinopathies;   Metabolic Disorders
Intervention: Biological: BPX-501 and AP1903
12 Recruiting Reduced Intensity Conditioning in Patients Aged ≤35 With Non-Malignant Disorders Undergoing UCBT, BMT, or PBSCT
Conditions: Primary Immunodeficiency Syndromes;   Congenital Bone Marrow Failure Syndromes;   Inherited Metabolic Disorders (IMD);   Hereditary Anemias;   Patients With Sickle Disease Presenting Specific Symptoms
Interventions: Drug: Hydroxyurea;   Drug: Alemtuzumab;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Thiotepa

Indicates status has not been verified in more than two years